Participating sites

  • PI: Prof Ranjit Manchanda

  • PI: Dr Nicola MacDonald

  • PI: Dr Kevin Monahan

  • PI: Dr Ketan Gajjar

  • PI: Dr Claire Newton

  • PI: Dr Laura Tookman

  • PI: Dr Fatima El-Khouly

  • PI: Prof Emma Crosbie

  • PI: Dr Mahalakshmi Gurumurthy

  • PI: Dr Ian Harley

  • CI: Dr Emma Cattell

  • CI: Dr Ashraf Azzabi

  • CI: Dr Partha Sengupta

  • PI: Dr David Constable-Phelps

  • PI: Dr Janos Balega

  • PI: Dr Timothy Duncan

  • PI: Dr Sonali Kaushik

  • PI: Dr Ioannis Biliatis

  • PI: Dr Natalia Povolotskaya

  • PI: Dr Omer Devaja

  • PI: Dr Rema Iyer

  • PI: Dr Rene Roux

  • PI: Prof Charlie Gourley

  • CI: Dr Andrew Phillips

  • CI: Dr Aarti Sharma

  • CI: Dr Neel Bhuva

Interactive map of sites

For patients randomised to the mainstreaming arm, sites will continue with routine standard practice with a small amount of additional data entry. For patients recruited to the direct-to-patient testing arm, the central team will take the responsibility of coordinating pre-test counselling, genetic testing, and return of genetic testing results to patients and their clinical team. Sites will be responsible for referring patients to local genetic service(s) as per site practices.

Clinical members of participating sites will also be asked to complete a questionnaire exploring the impact of direct-to-patient testing on their patients and their service.

Sites that are interested in delivering the DETECT-2 trial can contact the DETECT-2 team here.